- Home
- SHOT vs NVCT Comparison
SHOT vs NVCT Comparison
Compare SHOT & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- NVCT
- Stock Information
- Founded
- SHOT 2018
- NVCT 2020
- Country
- SHOT United States
- NVCT United States
- Employees
- SHOT N/A
- NVCT N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- SHOT Health Care
- NVCT Health Care
- Exchange
- SHOT Nasdaq
- NVCT Nasdaq
- Market Cap
- SHOT 137.3M
- NVCT 152.3M
- IPO Year
- SHOT 2020
- NVCT 2022
- Fundamental
- Price
- SHOT $0.65
- NVCT $6.43
- Analyst Decision
- SHOT
- NVCT Strong Buy
- Analyst Count
- SHOT 0
- NVCT 3
- Target Price
- SHOT N/A
- NVCT $15.33
- AVG Volume (30 Days)
- SHOT 12.3M
- NVCT 234.2K
- Earning Date
- SHOT 08-26-2025
- NVCT 08-05-2025
- Dividend Yield
- SHOT N/A
- NVCT N/A
- EPS Growth
- SHOT N/A
- NVCT N/A
- EPS
- SHOT N/A
- NVCT N/A
- Revenue
- SHOT N/A
- NVCT N/A
- Revenue This Year
- SHOT N/A
- NVCT N/A
- Revenue Next Year
- SHOT N/A
- NVCT N/A
- P/E Ratio
- SHOT N/A
- NVCT N/A
- Revenue Growth
- SHOT 246.36
- NVCT N/A
- 52 Week Low
- SHOT $0.23
- NVCT $4.44
- 52 Week High
- SHOT $1.77
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- SHOT 48.12
- NVCT 39.18
- Support Level
- SHOT $0.39
- NVCT $6.18
- Resistance Level
- SHOT $0.69
- NVCT $6.99
- Average True Range (ATR)
- SHOT 0.21
- NVCT 0.50
- MACD
- SHOT -0.05
- NVCT -0.03
- Stochastic Oscillator
- SHOT 27.19
- NVCT 31.18
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.